These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
304 related items for PubMed ID: 9786168
1. D-amino acid-substituted analogs of corticotropin-releasing hormone (CRH) and urocortin with selective agonist activity at CRH1 and CRH2beta receptors. Wei ET, Thomas HA, Christian HC, Buckingham JC, Kishimoto T. Peptides; 1998; 19(7):1183-90. PubMed ID: 9786168 [Abstract] [Full Text] [Related]
2. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Carlson KW, Nawy SS, Wei ET, Sadée W, Filov VA, Rezsova VV, Slominski A, Quillan JM. Anticancer Res; 2001; 21(2A):1173-9. PubMed ID: 11396159 [Abstract] [Full Text] [Related]
3. [D-Pro5]Corticotropin-releasing factor analogs as selective agonists at corticotropin-releasing factor receptors. Wei ET, Thomas HA, Price JS, Kishimoto T. Eur J Pharmacol; 1996 Jun 13; 306(1-3):161-4. PubMed ID: 8813628 [Abstract] [Full Text] [Related]
5. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C. Nature; 1995 Nov 16; 378(6554):287-92. PubMed ID: 7477349 [Abstract] [Full Text] [Related]
6. Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats. Turnbull AV, Vale W, Rivier C. Eur J Pharmacol; 1996 May 15; 303(3):213-6. PubMed ID: 8813571 [Abstract] [Full Text] [Related]
7. Effect of urocortin and its interaction with adrenocorticotropin (ACTH) secretagogues on ACTH release. Ozawa M, Oki Y, Watanabe F, Iino K, Masuzawa M, Iwabuchi M, Yoshimi T. Peptides; 1998 May 15; 19(3):513-8. PubMed ID: 9533639 [Abstract] [Full Text] [Related]
8. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW. Proc Natl Acad Sci U S A; 2001 Jun 19; 98(13):7570-5. PubMed ID: 11416224 [Abstract] [Full Text] [Related]
9. Corticotropin-releasing hormone receptor expression and functional coupling in neonatal cardiac myocytes and AT-1 cells. Heldwein KA, Redick DL, Rittenberg MB, Claycomb WC, Stenzel-Poore MP. Endocrinology; 1996 Sep 19; 137(9):3631-9. PubMed ID: 8756527 [Abstract] [Full Text] [Related]
10. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. Pedersen WA, Wan R, Zhang P, Mattson MP. J Neurosci; 2002 Jan 15; 22(2):404-12. PubMed ID: 11784785 [Abstract] [Full Text] [Related]
11. Urocortin and inflammation: confounding effects of hypotension on measures of inflammation. Torpy DJ, Webster EL, Zachman EK, Aguilera G, Chrousos GP. Neuroimmunomodulation; 1999 Jan 15; 6(3):182-6. PubMed ID: 10213916 [Abstract] [Full Text] [Related]
12. Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro. Leitch IM, Boura AL, Botti C, Read MA, Walters WA, Smith R. J Clin Endocrinol Metab; 1998 Dec 15; 83(12):4510-3. PubMed ID: 9851801 [Abstract] [Full Text] [Related]
13. Cloning and characterization of human urocortin. Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW. Endocrinology; 1996 May 15; 137(5):2167-70. PubMed ID: 8612563 [Abstract] [Full Text] [Related]
14. Regulation of pituitary corticotropin releasing hormone receptors. Aguilera G, Rabadan-Diehl C, Nikodemova M. Peptides; 2001 May 15; 22(5):769-74. PubMed ID: 11337090 [Abstract] [Full Text] [Related]
15. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. Bakshi VP, Smith-Roe S, Newman SM, Grigoriadis DE, Kalin NH. J Neurosci; 2002 Apr 01; 22(7):2926-35. PubMed ID: 11923457 [Abstract] [Full Text] [Related]
16. Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies. Rominger DH, Rominger CM, Fitzgerald LW, Grzanna R, Largent BL, Zaczek R. J Pharmacol Exp Ther; 1998 Jul 01; 286(1):459-68. PubMed ID: 9655891 [Abstract] [Full Text] [Related]
17. Correlation of neuroendocrine and anti-edema activities of alanine-corticotropin-releasing factor analogs. Wei ET, Thomas HA. Eur J Pharmacol; 1994 Oct 03; 263(3):319-21. PubMed ID: 7843271 [Abstract] [Full Text] [Related]
18. Cloning and functional pharmacology of two corticotropin-releasing factor receptors from a teleost fish. Pohl S, Darlison MG, Clarke WC, Lederis K, Richter D. Eur J Pharmacol; 2001 Nov 02; 430(2-3):193-202. PubMed ID: 11711031 [Abstract] [Full Text] [Related]
19. Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hillhouse EW. Mol Endocrinol; 2000 Dec 02; 14(12):2076-91. PubMed ID: 11117536 [Abstract] [Full Text] [Related]
20. Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Facci L, Stevens DA, Pangallo M, Franceschini D, Skaper SD, Strijbos PJ. Neuropharmacology; 2003 Oct 02; 45(5):623-36. PubMed ID: 12941376 [Abstract] [Full Text] [Related] Page: [Next] [New Search]